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Summary Immunoreactivity for c-erbB-2 oncogene product expression has been investigated in patients with
breast cancer using the polyclonal antibody 21N. Three series of patients were studied, 602 presenting with
primary operable cancer, 57 with stage 3 and 123 with stage 4 disease. Representative tissue sections of each
primary tumour were stained using a standard immunoperoxidase technique. Invasive tumour membrane
immunoreactivity was assessed and identified in 15% of patients with primary operable cancer and 20% in the
advanced breast cancer group. The results demonstrate a relationship between poorer survival and oncogene
expression in all three patient groups. Patients in the primary operable cancer group with membrane
oncoprotein expression had a poorer outcome, 35% 10-year survival, compared with those in which membrane
expression was absent, 55% 10-year survival. The median survival of patients with stage 3 disease with
c-erbB-2 membrane positivity was 17 months compared to 24 months with membrane negativity. In stage 4
disease median survival with membrane expression was 8.8 months compared to 19.7 months with no
membrane expression. In addition in the series of primary cancers a correlation existed between histological
grade and membrane immunoreactivity. Multivariate analysis showed histological grade to be a more powerful
prognostic factor than c-erbB-2 protein expression. In conclusion, this study demonstrates, in a large series of
patients presenting to one centre, that c-erbB-2 protein expression is a prognostic indicator in patients with
primary operable and advanced breast disease.
The proto-oncogene c-erbB-2 (also known as neu or HER-2)
is a 190 kilodalton transmembrane glycoprotein similar in
structure to the epidermal growth factor receptor (EGFR)
(Coussens et al., 1985). The extracellular domains of the two
proteins are 40% identical in sequence and both possess two
regions rich in cysteine residues which may be responsible for
stabilisation of their three dimensional structure and ability
to bind ligands. No ligand has yet however been definitively
identified for the c-erbB-2 protein although an activity pre-
sent in the conditioned medium of ras transformed cells has
bene reported (Yarden & Weinberg, 1989). The two proteins
are also identical in sequence in about 80% of their amino
acids forming the intracellular tyrosine kinase domain.
The c-erbB-2 protein was originally identified in rats where
it is generally called neu. In a transplacental chemical car-
cinogenesis model an activated oncogene was isolated which
was later determined to be a mutated form of neu. The
mutation occurred in a specific residue in the transmembrane
sequence (Bargmann & Weinberg, 1989) which stabilised
receptor dimerisation and activated its tyrosine kinase
(Weiner et al., 1989). A model of the three dimensional
structure of this region suggests that dimerisation is stabilised
by hydrogen bonding (Sternberg & Gullick, 1989).
Monoclonal antibodies which bind to and down regulate
mutant receptor expression inhibit tumour cell growth in
vitro and in vivo (Maguire & Greene, 1989). Overexpression
of the normal c-erbB-2 protein in NIH 3T3 cells leads to
transformation (Di Fiore et al., 1987; Hudziak et al., 1987).
The c-erbB-2 protein is overexpressed in 15-20% of human
invasive cancers (Gullick & Venter, 1989) and in a high
proportion of ductal carcinomas in situ of the comedo type
(Van de Vijver et al., 1988 b) and in cases of Pagets disease
of the nipple (Lammie et al., 1989). Recently antibodies to
natural human c-erbB-2 have been shown to inhibit the
growth of the breast cancer derived cell line SKBR-3 which
expresses high levels of the protein (Hudziak et al., 1989).
There has been increasing interest in the role of c-erbB-2
oncogene in breast cancer, particularly its relationship to
prognosis (Barnes, 1989). Overexpression of c-erbB-2
oncogene has been shown to correlate with poor prognosis in
both primary operable and advanced breast cancer patients
by some groups (Varley et al., 1987; Slamon et al., 1987;
Walker et al., 1989; Tsuda et al., 1989; Wright et al., 1989;
Slamon et al., 1989; Tandon et al., 1989; Paik et al., 1990)
but this significant association has not been demonstrated by
others (Cline et al., 1987; Van de Vijver et al., 1988a; Barnes
et al., 1988; Gusterson et al., 1988; Ali et al., 1988; Zhou et
al., 1989) and remains controversial. c-erbB-2 oncogene pro-
duct can be detected immunohistologically in patients with
breast cancer. Previous studies with the antibody 21N and
others, using southern blotting and immunohistological stain-
ing have demonstrated that tumour cell membrane reactivity
is related to c-erbB-2 gene amplification (Venter et al., 1987;
Gusterson et al., 1987). Use of immunohistology to detect
elevated levels of c-erbB-2 protein expression allows study of
archival tumour samples from well characterised series. In
this study we have examined, in a large series of patients
managed by a single team, the prognostic effect of c-erbB-2
oncoprotein expression in primary and advanced breast car-
cinoma and its value in relationship to existing prognostic
factors.
Methods
The patients in this study presented with primary operable or
advanced breast cancer to a single surgical team (Professor
R.W. Blamey) at the City Hospital, Nottingham. Seven hun-
dred and eighty-two patients with breast cancer were initially
entered in the study, 602 consecutive patients with primary
operable breast cancer, 57 presenting with stage 3 and 123
with stage 4 disease. Of those patients with primary operable
cancer 497 had sufficient tumour material available for
immunohistochemical assessment. All 180 cases in the
advanced breast cancer group had sufficient histological
material, giving a total of 667 suitable cases.
Patients were followed up after surgery at 3 monthly inter-
vals for 18 months and thereafter 6 monthly for 5 years, then
annually. Overall survival was taken from the time of
original diagnosis to the time of death.
The excised tumours were measured in their fresh state by
bisection in two planes, and measurements made in three at
right angles. Tumour size was taken as the largest of these
three dimensions. The tissue was immersed immediately in
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neutral buffered formalin and allowed to fix for 24 h. The
tumour blocks were then processed, embedded routinely in
paraffin wax and stored.
A polyclonal antibody 21N (Gullick et al., 1987), raised in
rabbits using a synthetic peptide identical in sequence to the
predicted C terminus of the c-erbB-2 protein (residues
1243-1255), was used to demonstrate the presence of onco-
protein expression in the primary tumours by a standard
immunoperoxidase technique. Three tLM sections were cut
and dewaxed in xyiene and rinsed in absolute alcohol.
Endogenous peroxidase activity was blocked with hydrogen
peroxide in methanol and non specific binding sites were
blocked using 10% normal swine serum. This was followed
by incubation in affinity purified primary antibody used at a
concentration of 3.93 tLg ml-'. This concentration has
previously been demonstrated to delineate membrane reac-
tivity in tumours with known oncogene amplification. Bind-
ing of the primary antibody was demonstrated by a standard
Avidin Biotin Complex technique. This method uses biotiny-
lated swine anti rabbit immunoglobulin followed by
preformed soluble complexes of avidin and biotinylated
horse radish peroxidase (Dako). The reaction is developed
using 0.05% diaminobenzidine with 0.03% hydrogen perox-
ide in Tris buffer at pH 7.6 for 10 min. The sections were
counterstained with haematoxylin. Sections were also pro-
cessed in the absence of 21N antibody to act as a negative
control and two tumours of known immunoreactivity were
stained as positive controls.
Studies using the antibody 21N have demonstrated a direct
association between tumour cell membrane reactivity and
oncogene product expression using western blotting tech-
nology. On the basis of these observations tumours were
classified according to their immunoreactivity as either
positive or negative. Prior to commencement of the study it
was decided to assess heterogeneity of immunoreactivity.
Only a small proportion of patients showed heterogeneous
staining; this was invariably in excess of 50% of tumour cells
and subclassification based on this criterion was considered
inappropriate. For the purpose of this study these cases
exhibiting heterogeneous reactivity were classified as positive.
Membrane immunoreactivity was analysed independently by
two observers without any prior knowledge of clinical data
and in rare cases of discrepancy, a consensus opinion was
sought.
In the primary group of patients lymph node sampling was
carried out at the time of surgery and on the basis of
histological assessment, patients were further categorised into
the following groups: lymph node stage A = no nodal
involvement, lymph node stage B = low axillary node alone
involved, lymph node stage C = apical and/or internal mam-
mary node involved.
Information on histological grade, tumour size, lymph
node status, vascular invasion, and survival was recorded for
all cases. Oestrogen receptor content was measured at the
Tenovus Institute using the Dextran coated charcoal method;
a seven point assay was employed and the results were
computed by Scatchard analysis. Tumours with an oestrogen
receptor content greater than 5 femtomoles per mg of cytosol
protein were considered positive. All histological grades were
assessed independently by two pathologists (IOE and CWE)
using Elston's modification (Elston, 1987) of the Bloom and
Richardson method. This technique assesses nuclear pleo-
morphism, mitotic frequency and tubule formation. Any dis-
crepancy of grading was resolved by review and consensus
opinion using a dual headed microscope.
Results
Primary operable breast cancer
Seventy-five of the 497 patients (15%) of the primary series
showed positive membrane immunoreactivity with 21N
(Figure 1). Cytoplasmic staining was present to varying
degrees but for the purpose of this study was not analysed
Figure 1 A case of invasive adenocarcinoma of breast showing
positive tumour cell membrane immunoreactivity with antibody
21N.
further. Using life table analysis a highly signficiant correla-
tion was found between poorer survival and invasive tumour
cell membrane staining (Figure 2). A significant relationship
was also demonstrated between worsening histological grade,
which could be assessed in 480 patients, and membrane
immunoreactivity (Table I). No correlation was found
between membrane expression and lymph node status, oest-
rogen receptor status and vascular invasion.
Complete lymph node stage data was available on 479 of
these patients. Two hundred and fifty patients were lymph
node negative. Comparison of Stage A (lymph node negative)
with Stages B and C (operable lymph node positive) patients
(Figure 3) according to c-erbB-2 statistics shows no
significant difference in survival between c-erbB-2 positive
and negative lymph node negative patients. Significant
differences in survival were found between c-erbB-2 negative,
node negative and positive patients, c-erbB-2 positive node
negative and positive patients, and node positive c-erbB-2
0 1 2 3 4 5 i 8 910 11 12 Time (years)
Number 422 333 232 143 41 cerbB2 -ve
at risk 75 47 27 20 3 cerbB2 +ve
Figure 2 Survival of patients with operable breast carcinoma
according to tumour immunoreactivity for 21N.
Table I The relationship between histological grade and tumour
immunoreactivity for 2iN in primary operable breast carcinoma
21N immunoreactivity
Negative Positive % Total
Histological 1 73 2 (3) 75
Grade 2 156 19 (11) 175
3 181 49 (21) 230
Total 410 70 (15) 480
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Figure 4 Survival of patients with stage 3 breast carcinoma
according to tumour immunoreactivity for 21N.
0 1 2 3 4 5 6 7 8 9 10 11 12 Time
Number 219 193 145 99 31 (a)
at risk 31 27 17 14 2 (b)
189 127 75 35 8 (c)
40 18 8 5 0 (d)
Figure 3 Survival for patients with operable breast cancer ac-
cording to tumour immunoreactivity for 21N and lymph node
stage. Pairwise comparison statistics for the four groups gave the
following results: a vs b P=0.23; a vs c P<0.0001; a vs d
P<0.0001; b vs c P=0.023; b vs d P<0.0001; c vs d
P = 0.003.
positive and negative patients. A lower prevalance of c-erbB-
2 immunoreactivity was observed in node negative disease,
12.4% vs stage B/C (node positive disease) - 17.4%.
Multivariate analysis (Cox, 1972) was used to identify
whether c-erbB-2 was of independent prognostic significance.
In the context of the temporal variables, tumour size and
lymph node stage, cell membrane staining was found to have
independent significance as a prognostic factor (Table lIla)
but significance was lost when histological grade was
included in the analysis (Table IIIb).
Advanced breast cancer
In the group of patients with advanced breast cancer 36 of
the 180 patients (20%) showed membrane immunoreactivity.
A positive correlation was seen between survival and 21N
immunoreactivity in both stage 3 (Figure 4) and stage 4
patients (Figure 5). No association was demonstrated
Table II The relationship between oestrogen receptor status and
tumour immunoreactivity for 21N in patients with advanced breast
carcinoma. Oestrogen receptor status was measured on 146
patients
21N immunoreactivity
Negative Positive Total
Oestrogen Positive 70 10 80
Receptor Negative 43 23 66
Status Total 103 33 146
x= 9.08; 1 degree of freedom P <0.003.
Table III Results of the Cox Multivariate analysis. 21N
immunoreactivity, tumour size and lymph node status were entered
with (analysis 1) and without (analysis 2) inclusion of histological
grade
Analysis I Analysis 2
P coeff. Z value l coeff. Z value
Tumour size 0.16 3.31 0.176 3.47
Lymph node stage 0.69 7.84 0.603 6.23
AP21N Immiunoreactivity Not significant 0.528 2.85
Histological grade 0.73 6.75 Not entered
Z values of <1.96 are significant (P <0.02).
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Figure 5 Survival of patients with stage 4 breast carcinoma
according to tumour immunoreactivity for 21N.
between tumour membrane immunoreactivity and tumour
size, histological grade, lymph node status and vascular
invasion. A weak inverse relationship existed between oest-
rogen receptor status and oncogene expression; that is
tumours showing positive membrane immunoreactivity
tended to be oestrogen receptor negative (Table II).
Discussion
Assessment of c-erbB-2 proto-oncogene overexpression can
be achieved using immunocytochemistry on formalin fixed
paraffin embedded tumour material to identify membrane
localisation of the oncoprotein. Various studies have
confirmed a relationship between c-erbB-2 gene amplification
and immunohistological demonstration of membrane expres-
sion of the oncoprotein (Slamon et al., 1987; Venter et al.,
1987) and it has been argued that this approach is the most
appropriate for routine evaluation (Barnes, 1989). In our
series, using the antibody 21N, membrane expression of c-
erbB-2 protein was found in 15% of primary carcinomas and
in 20% of advanced breast carcinomas. We have demon-
strated a statistically significant relationship between poorer
survival and positive invasive tumour cell membrane
immunoreactivitiy in both primary and advanced breast
cancer patients. In primary disease, the relationship was
significant only in lymph node positive patients. The lower
prevelance of c-erbB-2 positivity in the node negative group
may have affected this result. In addition life events occurring
in the node negative group are less concentrated in the earlier
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years of follow-up. We believe that identification of an effect
of c-erbB-2 status in node negative patients would require a
study of a larger number of patients with longer follow-up.
Our series is of particular importance being the largest
reported and comprising a consecutive series of patients with
primary operable breast cancer presenting to and being
treated by a single centre. It should end the controversy
concerning the prognostic value of c-erbB-2 immunore-
activity. The findings are consistent with most other reports
(Varley et al., 1987; Slamon et al., 1987; Walker et al., 1989;
Tsuda et al., 1989; Wright et al., 1989; Slamon et al., 1989;
Tandon et al., 1989) but less significant (Van de Vijver et al.,
1988a; Barnes et al., 1988) and opposing results have been
reported (Cline et al., 1987; Gusterson et al., 1988; Ali et al.,
1988; Zhou et al., 1989). Although significant, the association
shown with survival appears to be less powerful than some
existing prognostic factors. The low percentage, 15-20% in
most series, of invasive breast carcinoma showing gene
amplification requires that large numbers of patients are
studied before a significant relationship with prognosis can
be demonstrated. This observation alone could explain most
of the discrepancies observed between reported series.
Investigation of relationships between c-erbB-2 positive
membrane immunoreactivity and established prognostic fac-
tors showed no correlation, in our study, with the time
dependent variables of lymph node stage and tumour size.
This finding is similar to those of some groups (Van der
Vijver et al., 1988a; Slamon et al., 1987; Tsuda et al., 1989;
Tandon et al., 1989; Cox, 1972) but is inconsistent with
others (Cline et al., 1987; Rio et al., 1987; Berger et al., 1988;
Guerin et al., 1989; Seshadri et al., 1989; Borg et al., 1989)
who showed a positive correlation between c-erbB-2 onco-
protein and positive nodal status. Two groups have reported
an association with tumour size (Van de Vijver et al., 1988a;
Borg et al., 1989) but others have not (Cline et al., 1987;
Slamon et al., 1987; Tsuda et al., 1989; Wright et al., 1989;
Tandon et al., 1989). In the larger series of patients with
primary operable cancer we have demonstrated a positive
correlation between worsening histological grade and positive
membrane immunoreactivity. A similar observation has been
made by some groups (Zhou et al., 1987; Barnes et al., 1988;
Berger et al., 1988; Walker et al., 1989; Wright et al., 1989;
Paik et al., 1990) but others have not identified such a
relationship (Rio et al., 1987; Van de Vijver 1988a; Guerin et
al., 1989). We failed to confirm a similar relationship with
histological grade in the advanced breast cancer series. Some
of these discrepancies could be explained by differences in
selection criteria for patients entered into a particular study
and again the low frequency of c-erbB-2 protein expression
and low numbers of patients studied.
There are many recognised prognostic factors in human
breast cancer. In our breast cancer series we have previously
demonstrated that the most powerful factors are lymph node
stage, histological grade and tumour size (Todd et al., 1987).
The multivariate analysis in this study indicates that c-erbB-2
protein expression is a significant prognostic factor only
when assessed with the time related prognostic factors,
tumour size and lymph node stage. When the powerful
tumour related prognostic factor, histological grade, was
introduced into the analysis the independent significance of
c-erbB-2 protein expression was lost. c-erbB-2 amplification
is found in only a small proportion of tumours and for this
reason alone it is perhaps not surprising that it fails to
provide prognostic information of a magnitude similar to
histological grade. It is difficult to speculate on the potential
value of knowledge of elevated c-erbB-2 protein expression
without precise knowledge of its function (see below).
Speculation that amplification and over expression of certain
genes may be reflected in tumour cell morphology (Cardiff,
1988) has been partly borne out by evidence that c-erbB-2
amplification is related to large cell morphology, particularly
in ductal carcinoma in situ (Van de Vijver et al., 1988b).
Histological grading is assessed by combining the appearance
of various morphological features and mitotic figure fre-
quency (Elston, 1987). It thus provides a summation of a
variety of tumour variables. Extrapolating further from the
above tentative evidence, one could suggest that histological
grade gives an overview of various molecular events affecting
morphological appearance. It is unlikely therefore that a
single molecular event could compete with histological grade
in such a statistical multivariate analysis. We believe the
future clinical application of molecular markers of prognosis
will be in combination, providing information analogous to
histological grade.
Our knowledge of the function of c-erbB-2 oncoprotein is
rudimentary. It has similarities to EGFR and there is
sufficient evidence to indicate that its role as a membrane
receptor for a ligand, yet unknown, is likely. It is persistently
overexpressed in a significant proportion of breast car-
cinomas and clearly delineates a poorer prognostic subgroup.
Further support for c-erbB-2's growth regulatory role is the
observation that monoclonal antibodies raised against the
extracellular domain (Drebin et al., 1986) have exerted an
antitumour effect on mutant neu transformed NIH 3T3 cells
and on human breast tumour derived cell line. In addition we
know that EGFR expression is associated with poorer prog-
nosis and one might postulate that EGFR and c-erbB-2
oncoprotein are both components of a mechanism respon-
sible for breast tumours or progression. Certainly Kadowaki
et al. (1987) has demonstrated that c-erbB-2 oncoprotein can
act as a substrate for EGFR tyrosine kinase. A possible
hypothesis, of course, is that binding of ligand to increasing
number of receptors leads to an elevation in phosphokinase
activity which would promote cell replication. It has recently
been demonstrated that a combination of expression of
EGFR and c-erbB-2 more efficiently transforms cells than
either protein alone (Kokai et al., 1989).
In summary, our study has confirmed that c-erbB-2
overexpression is an important molecular prognostic
indicator in breast carcinoma and clearly delineates a poorer
prognostic subgroup. This information has clinical implica-
tions and if the ligand receptor hypothesis is correct a new
chemotherapeutic dimension may be introduced once more
knowledge is acquired on a molecular biological level.
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